40,000 Shares in Progyny, Inc. $PGNY Bought by Calamos Advisors LLC

Calamos Advisors LLC purchased a new position in Progyny, Inc. (NASDAQ:PGNY) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 40,000 shares of the company’s stock, valued at approximately $679,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in Progyny by 16.4% during the 1st quarter. Principal Financial Group Inc. now owns 554,916 shares of the company’s stock worth $9,422,000 after acquiring an additional 78,198 shares during the period. Fifth Third Bancorp grew its position in Progyny by 8,354.1% in the 1st quarter. Fifth Third Bancorp now owns 58,249 shares of the company’s stock valued at $989,000 after buying an additional 57,560 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. increased its stake in Progyny by 141.9% during the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 170,076 shares of the company’s stock valued at $2,888,000 after buying an additional 99,764 shares during the period. Strs Ohio raised its position in shares of Progyny by 25.3% during the 1st quarter. Strs Ohio now owns 41,600 shares of the company’s stock worth $706,000 after buying an additional 8,400 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH raised its position in shares of Progyny by 46.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after buying an additional 859,289 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Insiders Place Their Bets

In other news, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the transaction, the insider owned 59,117 shares in the company, valued at approximately $1,512,212.86. The trade was a 2.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Allison Swartz sold 1,199 shares of Progyny stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $25.02, for a total value of $29,998.98. Following the sale, the executive vice president directly owned 83,316 shares in the company, valued at $2,084,566.32. The trade was a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 36,916 shares of company stock valued at $939,875 in the last 90 days. 9.90% of the stock is currently owned by corporate insiders.

Progyny Trading Down 1.5%

NASDAQ PGNY opened at $31.86 on Friday. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $33.06. The firm’s fifty day simple moving average is $26.91 and its 200-day simple moving average is $22.84. The company has a market capitalization of $2.50 billion, a PE ratio of 41.38, a price-to-earnings-growth ratio of 2.57 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. The business had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.46 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. Progyny’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, analysts predict that Progyny, Inc. will post 1.19 EPS for the current year.

Progyny declared that its Board of Directors has initiated a stock buyback plan on Tuesday, May 26th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to buy up to 10.3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PGNY. Truist Financial increased their price target on Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Bank of America raised their target price on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Barclays boosted their price target on shares of Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. KeyCorp upped their price target on shares of Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday. Finally, Citigroup restated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $30.73.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.